Piperacillin Tazobactum

# Piperacillin Tazobactum ## Overview - **Classification**: Penicillin antibiotic combined with a beta-lactamase inhibitor. - **Mechanism**: Piperacillin inhibits bacterial cell wall synthesis. Tazobactam protects piperacillin from degradation by beta-lactamase enzymes, expanding its spectrum. ## Primary Indications 1. **Intra-abdominal Infections** - Complicated (cIAI). 2. **Skin and Skin Structure Infections** - Complicated (cSSSI). 3. **Gynecological Infections** - Postpartum endometritis, Pelvic Inflammatory Disease (PID). 4. **Community-acquired Pneumonia (CAP)** - Moderate to severe. 5. **Healthcare-associated Pneumonia (HAP)** - Including ventilator-associated pneumonia (VAP). 6. **Febrile Neutropenia** - Empiric treatment. ## Adult Dosing ### Standard Dosing **Most Infections (cIAI, cSSSI, CAP, Gynecological)** - **Dose**: **3.375 g IV** - **Frequency**: Every 6 hours - **Route**: Intravenous infusion over 30 minutes - **Duration**: 5-14 days depending on infection **Healthcare-associated Pneumonia, Febrile Neutropenia, or other Severe Infections** - **Dose**: **4.5 g IV** - **Frequency**: Every 6 hours - **Route**: Intravenous infusion over 30 minutes - **Max Dose**: **18 g/day** **Extended Infusion for Severe Infections (e.g., HAP, critically ill)** - **Dose**: **3.375 g IV** - **Frequency**: Every 8 hours - **Route**: Intravenous infusion over 4 hours - **Max Dose**: **13.5 g/day** (equivalent to 4.5 g q6h standard infusion) ### Dose Adjustments - **Renal Impairment**: - CrCl >40 mL/min: No adjustment. - CrCl 20-40 mL/min: **2.25 g IV every 6 hours** (for standard 3.375 g q6h dose). - CrCl <20 mL/min: **2.25 g IV every 8 hours** (for standard 3.375 g q6h dose). - Hemodialysis: **2.25 g IV every 12 hours**; administer **0.75 g IV** post-dialysis on dialysis days. - **Hepatic Impairment**: No specific dose adjustment generally recommended. Use with caution, monitor LFTs. - **Elderly Patients**: No specific adjustment solely for age, but assess renal function carefully. ## Pediatric Dosing ### Neonates (0-28 days) - **Indication**: Serious infections (e.g., sepsis, pneumonia) - **Dose**: **80 mg/kg/dose IV** (piperacillin component) - **Frequency**: - Postnatal age ≤7 days: **Every 12 hours** - Postnatal age >7 days: **Every 8 hours** - **Maximum**: Not to exceed adult doses. - **Special Notes**: Consider gestational age and renal function. Prolonged infusion may be beneficial. ### Infants (1-12 months) - **Indication**: Serious infections (e.g., cIAI, pneumonia) - **Dose**: **80 mg/kg/dose IV** (piperacillin component) - **Frequency**: Every 6-8 hours - **Maximum**: **4.5 g/dose IV** (adult max single dose) - **Special Notes**: Use lowest effective dose. ### Children (1-12 years) - **Indication**: Moderate-severe infections (e.g., cIAI, cSSSI, CAP) - **Dose**: **80 mg/kg/dose IV** (piperacillin component) - **Frequency**: Every 6-8 hours - **Maximum**: **4.5 g/dose IV** (adult max single dose) - **Considerations**: For cystic fibrosis or severe infections, some sources recommend **100 mg/kg/dose every 6 hours**. ### Adolescents (13-18 years) - **Dose**: Generally follows **adult dosing** guidelines. - **Frequency**: Every 6-8 hours - **Maximum**: **4.5 g/dose IV** (18 g/day) ## Safety Information ### Contraindications - **Absolute**: History of severe allergic reaction (e.g., anaphylaxis, SJS) to piperacillin, tazobactam, penicillins, or other beta-lactam agents. - **Relative**: History of less severe penicillin allergy (rash); use with caution, monitor closely. ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea, Nausea, Headache, Insomnia. - **Common (1-10%)**: Rash, Vomiting, Constipation, Abdominal pain, Fever, Dyspepsia, Pruritus. - **Serious but Rare**: Anaphylaxis, Clostridioides difficile-associated diarrhea (CDAD), Seizures (especially with high doses/renal impairment), Leukopenia, Thrombocytopenia, Interstitial nephritis, Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN). ### Key Drug Interactions - **Aminoglycosides (e.g., Gentamicin)**: Piperacillin can inactivate aminoglycosides *in vitro*. Administer separately and monitor aminoglycoside levels. - **Methotrexate**: Piperacillin-tazobactam may reduce methotrexate excretion, increasing toxicity. Monitor methotrexate levels. - **Oral Anticoagulants (e.g., Warfarin)**: May alter platelet aggregation and prothrombin time, increasing bleeding risk. Monitor INR closely. - **Vecuronium**: Piperacillin can prolong neuromuscular blockade. Monitor for respiratory depression. ## Monitoring & Follow-up - **Before Treatment**: Culture and sensitivity testing (if possible), renal function (BUN/Cr), liver function tests (ALT/AST). - **During Treatment**: - Renal function (BUN/Cr) daily for first few days, then periodically, especially in renal impairment. - CBC (WBC, platelets) periodically, especially with prolonged therapy (>10 days). - Liver function tests (ALT/AST) periodically. - Electrolytes (Potassium) in patients at risk for hypokalemia. - Signs of superinfection (e.g., oral candidiasis, C. difficile diarrhea). - **Clinical Signs**: Resolution of infection symptoms, development of rash, diarrhea, or other adverse effects. ## Clinical Pearls - 💡 **Extended Infusion**: For severe infections, particularly in critically ill patients, extended infusions (e.g., 3.375 g over 4 hours every 8 hours) are often preferred for optimized pharmacodynamics. - 💡 **Broad Spectrum**: Excellent broad-spectrum coverage against many Gram-positive, Gram-negative (including Pseudomonas aeruginosa), and anaerobic bacteria. - 💡 **Sodium Content**: Contains a significant amount of sodium per dose; monitor in patients with fluid overload or heart failure. - 💡 **Allergy Cross-reactivity**: While less common, cross-reactivity with cephalosporins and carbapenems can occur in patients with penicillin allergy. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.